LGND Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

55.59M

+29.84%

0.804

-149.01%

60.08M

+32.52%

1.404

-163.55%

63.52M

+33.38%

1.481

+517.07%

Estimates Revision

The market is revising No Change the revenue expectations for Ligand Pharmaceuticals Incorporated (LGND) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 13.34%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+13.34%

In Past 3 Month

6 Analyst Rating

Wall Street analysts forecast LGND stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LGND is 238.33 USD with a low forecast of 220.00 USD and a high forecast of 275.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

220.00

Averages

238.33

High

275.00

Current: 0.000

Low

220.00

Averages

238.33

High

275.00

Stifel

Buy

maintain

$220 -> $230

2025-12-10

Reason

Stifel

Price Target

$220 -> $230

2025-12-10

maintain

Buy

Reason

Stifel raised the firm's price target on Ligand to $230 from $220 and keeps a Buy rating on the shares after an investor day that the firm says covered "key growth drivers within its diverse royalty portfolio as well as recent value-creating transactions" that will support achieving the raised five-year royalty compound annual growth rate of greater than 23%.

Citi

NULL

Buy

initiated

$270

2025-12-09

Reason

Citi

Price Target

$270

2025-12-09

initiated

NULL

Buy

Reason

Citi initiated coverage of Ligand (LGND) with a Buy rating and $270 price target. The firm says the company's focus on royalties and platform out-licensing limits volatility and concentration risk. Citi believes the stock can re-rate further with data catalysts coming in the end of 2025 and 2026. Citi also added an "upside 90-day catalyst watch" on Ligand shares. It expects the company's partner Travere Therapeutics (TVTX) to receive FDA approval on or before the upcoming action date of January 13, 2026.

Oppenheimer

Outperform

upgrade

$250 -> $275

2025-11-07

Reason

Oppenheimer

Price Target

$250 -> $275

2025-11-07

upgrade

Outperform

Reason

Oppenheimer raised the firm's price target on Ligand to $275 from $250 and keeps an Outperform rating on the shares. The firm notes Ligand reported total revenue of $115.5M including $46.6M from royalties, $24.5M from Zelsuvmi's out-licensing, and a $28.6M gain on Pelthos sale. Oppenheimer is bullish on Palvella's two value-unlocking events over next 4 months, which should provide further comfort on Qtorin's commercial opportunity. The firm sees Qtorin as a key driver of future royalties.

Benchmark

Buy

maintain

$175 -> $220

2025-11-07

Reason

Benchmark

Price Target

$175 -> $220

2025-11-07

maintain

Buy

Reason

Benchmark raised the firm's price target on Ligand to $220 from $175 and keeps a Buy rating on the shares after the company reported better-than-expected results for Q3 and increased FY25 guidance.

Stifel

Annabel Samimy

Buy

maintain

$195 -> $220

2025-11-07

Reason

Stifel

Annabel Samimy

Price Target

$195 -> $220

2025-11-07

maintain

Buy

Reason

Stifel analyst Annabel Samimy raised the firm's price target on Ligand to $220 from $195 and keeps a Buy rating on the shares. Consistently exceeding expectations, Ligand posted Q3 revenues of $86.9M an adjusted EPS of $3.09, reflecting a strong win on project financing and diversified royalty portfolio with growth drivers that consistently beat consensus, the analyst tells investors in a research note. The firm added the the company continues to execute across deal types in a capital-hungry financing environment.

RBC Capital

NULL -> Outperform

maintain

$185 -> $234

2025-11-07

Reason

RBC Capital

Price Target

$185 -> $234

2025-11-07

maintain

NULL -> Outperform

Reason

RBC Capital raised the firm's price target on Ligand to $234 from $185 and keeps an Outperform rating on the shares after "another solid quarter" and 2025 guidance raise.

Valuation Metrics

The current forward P/E ratio for Ligand Pharmaceuticals Inc (LGND.O) is 35.39, compared to its 5-year average forward P/E of -9.93. For a more detailed relative valuation and DCF analysis to assess Ligand Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-9.93

Current PE

35.39

Overvalued PE

143.00

Undervalued PE

-162.86

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

18.47

Current EV/EBITDA

20.56

Overvalued EV/EBITDA

24.48

Undervalued EV/EBITDA

12.47

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

10.87

Current PS

14.95

Overvalued PS

12.88

Undervalued PS

8.85

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

LGND News & Events

Events Timeline

No data

News

4.5

01-08Yahoo Finance

S&P 500 and Dow Reverse Gains as Nasdaq Narrows Upturn

4.5

01-08Yahoo Finance

S&P 500 and Dow Retreat from Highs, Eli Lilly and Google Flash Buy Signals

4.0

2025-12-09CNBC

A Biotech Investment Option for Cautious Investors in a Volatile Sector

People Also Watch

Frequently Asked Questions

What is Ligand Pharmaceuticals Inc (LGND) stock price today?

The current price of LGND is 206.65 USD — it has increased 3.29 % in the last trading day.

What is Ligand Pharmaceuticals Inc (LGND)'s business?

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. It does this by financing, licensing its technologies or both. It operates two infrastructure-light royalty-generating IP platform technologies. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled FDA-approved products, including Gilead’s Veklury, Amgen’s Kyprolis, Baxter’s Nexterone, and Acrotech Biopharma’s Evomela. Its NITRICIL platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a range of indications. Its technologies also include HepDirect, LTP and BEPro Technology Platform, and Pelican Expression Technology. It has multiple alliances, licenses and other business relationships with various pharmaceutical companies.

What is the price predicton of LGND Stock?

What is Ligand Pharmaceuticals Inc (LGND)'s revenue for the last quarter?

Ligand Pharmaceuticals Inc revenue for the last quarter amounts to 115.46M USD, increased 122.85 % YoY.

What is Ligand Pharmaceuticals Inc (LGND)'s earnings per share (EPS) for the last quarter?

Ligand Pharmaceuticals Inc. EPS for the last quarter amounts to 5.68 USD, decreased -1556.41 % YoY.

What changes have occurred in the market's expectations for Ligand Pharmaceuticals Inc (LGND)'s fundamentals?

How many employees does Ligand Pharmaceuticals Inc (LGND). have?

Ligand Pharmaceuticals Inc (LGND) has 68 emplpoyees as of January 10 2026.

What is Ligand Pharmaceuticals Inc (LGND) market cap?

Today LGND has the market capitalization of 4.07B USD.